

**Question for written answer E-014826/2015
to the Commission
Rule 130
Jude Kirton-Darling (S&D)**

Subject: Impact of TTIP - benefits for cost of medicines and other pharmaceuticals

In a blog post of 17 April 2015, Commissioner Malmström wrote that 'TTIP can help us deliver better public services like health, education or water, by lowering the costs of the goods and services that governments have to buy – like uniforms, furniture or medicine'.¹

Yet the 'Factsheet on Pharmaceuticals in TTIP' does not mention any expected benefit in terms of costs from TTIP, and only refers to the Commission's objective of 'ensur[ing] standards of efficacy, quality and safety'.²

1. Does the Commission believe that TTIP can contribute to lowering the cost of medicines in the European Union?
2. What evidence is the Commission using to assess the potential benefits of TTIP for pharmaceuticals, either in terms of cost or in terms of efficacy, quality and safety?

¹ https://ec.europa.eu/commission/2014-2019/malmstrom/blog/debating-ttip-today-and-tomorrow_en

² http://trade.ec.europa.eu/doclib/docs/2015/january/tradoc_153010.4.7%20Pharmaceuticals.pdf